Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (Nasdaq: DTIL) priced an underwritten securities offering expected to raise approximately $125 million in gross proceeds. The offering comprises 10,235,077 common shares at $7.75 each and pre-funded warrants to purchase up to 5,893,964 shares. The warrants cost $7.749995 each, with a separate exercise price of $0.000005 per share. All securities will be sold by Precision.
Gross proceeds are before underwriting discounts, commissions and offering expenses. Precision expects closing on or about November 6, 2026, subject to customary closing conditions. The company intends to use net proceeds for continued research and development of PBGENE-HBV and PBGENE-DMD, working capital and general corporate purposes. New and existing investors are participating. TD Cowen and Guggenheim Securities are joint book-running managers.
Precision BioSciences (Nasdaq: DTIL) received independent safety-board endorsement to dose additional patients in its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD.
The first patient completed the initial eight-week safety observation period with no serious adverse events or adverse events of special interest reported. The independent Data Safety Monitoring Board identified no safety concerns and endorsed further dosing in Part 1. The study evaluates safety, tolerability and efficacy in ambulatory Duchenne muscular dystrophy patients ages 2 to 7 with mutations between exons 45 and 55. Precision plans safety and efficacy updates throughout 2027.
PBGENE-DMD previously received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations. The Rare Pediatric Disease designation means it may be eligible for a Priority Review Voucher.
Precision BioSciences (Nasdaq: DTIL) reported Phase 1 hepatitis B data supporting advancement of PBGENE-HBV into a global Phase 2 study. At the September 28, 2026 cutoff, 25 patients had received 59 administrations. Of 12 evaluable patients with detectable baseline pregenomic RNA (pgRNA), a marker of viral activity, 11 (92%) achieved undetectable levels, including all six at 0.4 mg/kg. All responders with at least six months of follow-up maintained undetectable pgRNA. Two patients' liver biopsies showed approximately 1-log and 1.5-log reductions in cccDNA, the persistent viral DNA reservoir. All 24 evaluable patients had hepatitis B surface antigen reductions. No dose-limiting toxicities occurred; infusion reactions and reversible liver enzyme elevations were observed. Precision selected 0.4 mg/kg for Phase 2 and expects dosing in the first quarter of 2027, with initial open-label data in the second half of 2027.
Precision BioSciences (DTIL) reported third-quarter 2026 financial results and advanced its hepatitis B and Duchenne muscular dystrophy clinical programs. Net loss narrowed to $7.6 million, or $0.28 per share, from $21.8 million, or $1.84 per share, a year earlier, primarily reflecting a non-cash warrant-liability gain. Revenue was zero.
Cash, cash equivalents and restricted cash totaled approximately $108.0 million at September 30. Precision expects runway through 2028, relying on existing cash and cash equivalents, operating discipline and availability of its at-the-market facility. PBGENE-HBV data are scheduled for presentation November 8, with the abstract available November 5. The first PBGENE-DMD patient was dosed in August; initial safety data are targeted for year-end 2026, followed by efficacy data expected in H1 and H2 2027.
Precision BioSciences (DTIL) will publish its third-quarter 2026 financial results and provide a business update on November 3, 2026.
Precision BioSciences (Nasdaq: DTIL) will deliver a late-breaking oral presentation on PBGENE-HBV at AASLD’s The Liver Meeting on November 8, 2026.
Man-Fung Yuen will present from 2:15–2:30 p.m. MST during the meeting, held November 5–9 in Denver, Colorado. The abstract is titled “Durable pgRNA loss in both HBeAg positive and negative patients treated with PBGENE-HBV supports path towards viral cure.” Pregenomic RNA, or pgRNA, is the precursor for hepatitis B viral DNA. PBGENE-HBV is being evaluated as a potential treatment for chronic hepatitis B in the Phase 1 ELIMINATE-B trial.
iECURE (DTIL)/b) reported updated clinical data from the ongoing Phase 1/2 trial of gene-insertion therapy ECUR-506 in neonatal-onset ornithine transcarbamylase (OTC) deficiency, presented at the SSIEM 2026 symposium. According to iECURE, dosing is complete in all three cohorts (low, intermediate, high), with nine participants treated.
As of July 28, 2026, ECUR-506 was generally well tolerated across dose levels, with no unexpected treatment-related safety events, thrombotic microangiopathy, or infusion reactions. In the low-dose cohort, annualized hyperammonemic events were reduced by 57% (p=0.02) and hyperammonemic crises by 74% (p=0.01) versus pre-treatment. Liver biopsies in two low-dose participants and serum PCSK9 reductions supported targeted hepatic editing. One participant achieved a complete clinical response, discontinuing ammonia scavengers and protein restriction, while the other two showed clinical improvements.
Precision BioSciences (Nasdaq: DTIL) has dosed the first patient in August in its Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD, an in vivo ARCUS-based gene-editing therapy for Duchenne muscular dystrophy (DMD). The first dosing occurred at Arkansas Children’s Hospital, a certified Duchenne and MDA care center.
PBGENE-DMD uses two ARCUS nucleases delivered in a single AAV vector to excise exons 45-55 of the dystrophin gene, aiming to enable endogenous production of near full-length functional dystrophin. According to Precision BioSciences, this design could be applicable to up to 60% of DMD patients with mutations in this hotspot region.
The FUNCTION-DMD study is currently enrolling ambulatory boys aged 2–7 years with mutations between exons 45 and 55 at multiple specialized U.S. Duchenne care centers, with initial safety data targeted by year-end 2026.
iECURE (NASDAQ: DTIL), a clinical-stage genome editing company, announced that data from its ongoing OTC-HOPE trial of ECUR-506 in infants with neonatal-onset ornithine transcarbamylase (OTC) deficiency will be featured in an oral presentation at the SSIEM Annual Symposium, held August 25-28, 2026, in Helsinki, Finland.
The talk will present updated safety observations, genome editing data on metabolic control from the low-dose cohort, and analyses of baseline disease severity versus clinical response. The oral presentation, titled “Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration (O-124),” is scheduled for Thursday, August 27, 3:30–5:00 p.m. EEST in Hall 5B, delivered by Julien Baruteau, M.D., Ph.D. iECURE will also exhibit at Booth B16, where its medical team will discuss the OTC-HOPE study and genome editing platform.
Precision BioSciences (Nasdaq: DTIL) reported Q2 2026 results and a business update, highlighting first clinical biopsy evidence from the Phase 1 ELIMINATE-B trial that PBGENE-HBV directly reduces hepatitis B cccDNA. A patient showed a 1-log reduction with <1% cccDNA remaining after two 0.4 mg/kg doses, and repeat dosing in another patient increased anti-cccDNA effect. pgRNA became durably undetectable in 100% of evaluable patients, with substantial S-antigen declines across all dose levels and no dose-limiting toxicities in 16 patients.
PBGENE-DMD advanced with two active Phase 1/2 FUNCTION-DMD trial sites now recruiting, and initial safety data targeted for year-end 2026. Cash, cash equivalents and restricted cash were $112.4 million at June 30, 2026, which Precision expects to fund operations and PBGENE-HBV and PBGENE-DMD data milestones through 2028. Q2 2026 R&D expenses were $12.4 million, G&A $6.8 million, and net loss was $32.7 million, including $13.5 million of other expense driven primarily by non-cash warrant liability revaluation.